Chromosome aberrations and HEY1-NCOA2 fusion gene in a mesenchymal chondrosarcoma

Oncology Reports

Volumn 32, Issue 1, 2014, Pages 40-44

  Panagopoulos, Ioannis ^a,b   Gorunova, Ludmila ^a,b   Bjerkehagen, Bodil ^a   Boye, Kjetil ^a   Heim, Sverre ^a,b  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

Author keywords

Cytogenetics; Fusion gene; HEY1 NCOA2; Mesenchymal chondrosarcoma

Indexed keywords

CYCLOPHOSPHAMIDE; DACTINOMYCIN; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; VINCRISTINE; BASIC HELIX LOOP HELIX TRANSCRIPTION FACTOR; CELL CYCLE PROTEIN; HEY1 PROTEIN, HUMAN; HYBRID PROTEIN; NCOA2 PROTEIN, HUMAN; NUCLEAR RECEPTOR COACTIVATOR 2; ONCOPROTEIN;

ADULT; ARTICLE; BONE METASTASIS; CANCER SURGERY; CASE REPORT; CHONDROSARCOMA; CHROMOSOME ABERRATION; CHROMOSOME BANDING PATTERN; FEMALE; FUSION GENE; GENE SEQUENCE; HEY1 NCOA2 GENE; HUMAN; IMMUNOHISTOCHEMISTRY; KARYOTYPE 46,XX; KARYOTYPING; LIMB TUMOR; MICROSCOPY; MULTIPLE CYCLE TREATMENT; MUSCLE TUMOR; NECK METASTASIS; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; BONE TUMOR; CHROMOSOME 8; EXON; FEMUR; GENETICS; HEAD AND NECK TUMOR; KARYOTYPE; PATHOLOGY; TUMOR CELL CULTURE;

ADULT; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; BONE NEOPLASMS; CELL CYCLE PROTEINS; CHONDROSARCOMA, MESENCHYMAL; CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN, PAIR 8; EXONS; FEMALE; FEMUR; HEAD AND NECK NEOPLASMS; HUMANS; KARYOTYPE; NUCLEAR RECEPTOR COACTIVATOR 2; ONCOGENE PROTEINS, FUSION; RECOMBINANT FUSION PROTEINS; TUMOR CELLS, CULTURED;

EID: 84903194965     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2014.3180     Document Type: Article

References (30)

1. Shakked RJ, Geller DS, Gorlick R and Dorfman HD: Mesenchymal chondrosarcoma: clinicopathologic study of 20 cases. Arch Pathol Lab Med 136: 61-75, 2012.
2. Weiss SW and Goldblum JR (eds): Enzinger and Weiss's Soft Tissue Tumors. Mosby, St Louis, MO, 2001.
3. Riedel RF, Larrier N, Dodd L, Kirsch D, Martinez S and Brigman BE: The clinical management of chondrosarcoma. Curr Treat Options Oncol 10: 94-106, 2009.
4. Cesari M, Bertoni F, Bacchini P, Mercuri M, Palmerini E and Ferrari S: Mesenchymal chondrosarcoma. An analysis of patients treated at a single institution. Tumori 93: 423-427, 2007. (Pubitemid 350203913)
5. Dantonello TM, Int-Veen C, Leuschner I, et al: Mesenchymal chondrosarcoma of soft tissues and bone in children, adolescents, and young adults: experiences of the CWS and COSS study groups. Cancer 112: 2424-2431, 2008.
6. Crosswell H, Buchino JJ, Sweetman R and Reisner A: Intracranial mesenchymal chondrosarcoma in an infant. Med Pediatr Oncol 34: 370-374, 2000.
7. Dobin SM, Donner LR and Speights VO Jr: Mesenchymal chondrosarcoma. A cytogenetic, immunohistochemical and ultrastructural study. Cancer Genet Cytogenet 83: 56-60, 1995.
8. Fletcher CD, Dal Cin P, de Wever I, et al: Correlation between clinicopathological features and karyotype in spindle cell sarcomas. A report of 130 cases from the CHAMP study group. Am J Pathol 154: 1841-1847, 1999. (Pubitemid 29262867)
9. Gatter KM, Olson S, Lawce H and Rader AE: Trisomy 8 as the sole cytogenetic abnormality in a case of extraskeletal mesenchymal chondrosarcoma. Cancer Genet Cytogenet 159: 151-154, 2005. (Pubitemid 40719385)
10. Mandahl N, Gustafson P, Mertens F, et al: Cytogenetic aberrations and their prognostic impact in chondrosarcoma. Genes Chromosomes Cancer 33: 188-200, 2002. (Pubitemid 34052500)
11. Naumann S, Krallman PA, Unni KK, Fidler ME, Neff JR and Bridge JA: Translocation der(13;21)(q10;q10) in skeletal and extraskeletal mesenchymal chondrosarcoma. Mod Pathol 15: 572-576, 2002. (Pubitemid 34521407)
12. Nyquist KB, Panagopoulos I, Thorsen J, et al: Whole-transcriptome sequencing identifies novel IRF2BP2-CDX1 fusion gene brought about by translocation t(1;5)(q42;q32) in mesenchymal chondrosarcoma. PLoS One 7: e49705, 2012.
13. Richkind KE, Romansky SG and Finklestein JZ: t(4;19) (q35;q13.1): a recurrent change in primitive mesenchymal tumors? Cancer Genet Cytogenet 87: 71-74, 1996. (Pubitemid 26113609)
14. Sainati L, Scapinello A, Montaldi A, et al: A mesenchymal chondrosarcoma of a child with the reciprocal translocation (11;22)(q24;q12). Cancer Genet Cytogenet 71: 144-147, 1993. (Pubitemid 24040014)
15. Szymanska J, Tarkkanen M, Wiklund T, et al: Cytogenetic study of extraskeletal mesenchymal chondrosarcoma. A case report. Cancer Genet Cytogenet 86: 170-173, 1996. (Pubitemid 26074813)
16. Wang L, Motoi T, Khanin R, et al: Identification of a novel, recurrent HEY1-NCOA2 fusion in mesenchymal chondrosarcoma based on a genome-wide screen of exon-level expression data. Genes Chromosomes Cancer 51: 127-139, 2012.
17. Mandahl N: Methods in solid tumour cytogenetics. In: Human Cytogenetics: Malignancy and Acquired Abnormalities. Rooney DE (ed). Oxford University Press, New York, pp165-203, 2001.
18. Schaffer LG, Slovak ML and Campbell LJ (eds): ISCN 2009: An International System for Human Cytogenetic Nomenclature. Karger, Basel, 2009.
19. Nakayama R, Miura Y, Ogino J, et al: Detection of HEY1-NCOA2 fusion by fluorescence in-situ hybridization in formalin-fixed paraffin-embedded tissues as a possible diagnostic tool for mesenchymal chondrosarcoma. Pathol Int 62: 823-826, 2012.
20. Carapeti M, Aguiar RC, Goldman JM and Cross NC: A novel fusion between MOZ and the nuclear receptor coactivator TIF2 in acute myeloid leukemia. Blood 91: 3127-3133, 1998. (Pubitemid 28193860)
21. Carapeti M, Aguiar RC, Watmore AE, Goldman JM and Cross NC: Consistent fusion of MOZ and TIF2 in AML with inv(8)(p11q13). Cancer Genet Cytogenet 113: 70-72, 1999. (Pubitemid 29354097)
22. Strehl S, Nebral K, Konig M, et al: ETV6-NCOA2: a novel fusion gene in acute leukemia associated with coexpression of T-lymphoid and myeloid markers and frequent NOTCH1 mutations. Clin Cancer Res 14: 977-983, 2008. (Pubitemid 351302542)
23. Sumegi J, Streblow R, Frayer RW, et al: Recurrent t(2;2) and t(2;8) translocations in rhabdomyosarcoma without the canonical PAX-FOXO1 fuse PAX3 to members of the nuclear receptor transcriptional coactivator family. Genes Chromosomes Cancer 49: 224-236, 2010.
24. Arbajian E, Magnusson L, Mertens F, Domanski HA, Vult von Steyern F and Nord KH: A novel GTF2I/NCOA2 fusion gene emphasizes the role of NCOA2 in soft tissue angiofibroma development. Genes Chromosomes Cancer 52: 330-331, 2013.
25. Jin Y, Möller E, Nord KH, et al: Fusion of the AHRR and NCOA2 genes through a recurrent translocation t(5;8)(p15;q13) in soft tissue angiofibroma results in upregulation of aryl hydrocarbon receptor target genes. Genes Chromosomes Cancer 51: 510-520, 2012.
26. Mosquera JM, Sboner A, Zhang L, et al: Recurrent NCOA2 gene rearrangements in congenital/infantile spindle cell rhabdomyosarcoma. Genes Chromosomes Cancer 52: 538-550, 2013.
27. Deguchi K, Ayton PM, Carapeti M, et al: MOZ-TIF2-induced acute myeloid leukemia requires the MOZ nucleosome binding motif and TIF2-mediated recruitment of CBP. Cancer Cell 3: 259-271, 2003. (Pubitemid 37443881)
28. Zhuravleva J, Paggetti J, Martin L, et al: MOZ/TIF2-induced acute myeloid leukaemia in transgenic fish. Br J Haematol 143: 378-382, 2008.
29. Steidl C, Leimeister C, Klamt B, et al: Characterization of the human and mouse HEY1, HEY2, and HEYL genes: cloning, mapping, and mutation screening of a new bHLH gene family. Genomics 66: 195-203, 2000. (Pubitemid 30429754)
30. Maier MM and Gessler M: Comparative analysis of the human and mouse Hey1 promoter: Hey genes are new Notch target genes. Biochem Biophys Res Commun 275: 652-660, 2000.